209526-98-7 Usage
Uses
Used in Organic Synthesis:
2-Pyridinemethanol,5-chloro-(9CI) is utilized as a key intermediate in organic synthesis for the development of more complex organic compounds. Its unique structure allows for various chemical reactions, making it a versatile component in the synthesis of a wide range of molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-Pyridinemethanol,5-chloro-(9CI) is used as a building block for the synthesis of potential drug candidates. Its distinct chemical properties and potential biological activity make it a valuable asset in the discovery and development of new medications.
Used in Medicinal Chemistry Research:
2-Pyridinemethanol,5-chloro-(9CI) is employed in medicinal chemistry research to explore its potential as a therapeutic agent. Its unique structure and possible biological activity are of interest to researchers seeking to understand its interactions with biological targets and its potential applications in treating various diseases.
Safety Precautions:
As with any chemical compound, it is crucial to follow proper handling and safety precautions when working with 2-Pyridinemethanol,5-chloro-(9CI). This includes minimizing potential hazards and risks associated with its use, ensuring the safety of researchers and the environment.
Check Digit Verification of cas no
The CAS Registry Mumber 209526-98-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,9,5,2 and 6 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 209526-98:
(8*2)+(7*0)+(6*9)+(5*5)+(4*2)+(3*6)+(2*9)+(1*8)=147
147 % 10 = 7
So 209526-98-7 is a valid CAS Registry Number.
InChI:InChI=1/C6H6ClNO/c7-5-1-2-6(4-9)8-3-5/h1-3,9H,4H2
209526-98-7Relevant academic research and scientific papers
Triazolopyridine cannabinoid receptor 1 antagonists
-
, (2008/06/13)
The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.
